DURECT Reports FDA  Anesthetic and Analgesic Drug Products Advisory Committee Met Thurs. To Discuss Class 2 New Drug Application for POSIMIR; 6 AdCom Members Voted To Recommend Efficacy, Safety, 6 Voted Against Recommendation